DEMADEX (torsemide) by PharmaIN is clinical pharmacology mechanism of action micropuncture studies in animals have shown that torsemide acts from within the lumen of the thick ascending portion of the loop of henle, where it inhibits the na/k/2ci-carrier system. Approved for heart failure. First approved in 1993.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
DEMADEX (torsemide) is a loop diuretic approved in 1993 that inhibits the Na/K/2Cl-carrier system in the thick ascending loop of Henle to increase urinary excretion of sodium, chloride, and water. It is indicated for heart failure and management of renal impairment-related fluid overload. The drug works by acting within the tubular lumen rather than systemically, correlating diuretic activity with urinary drug excretion.
As a mature product approaching loss of exclusivity, career opportunities on DEMADEX will likely focus on defending market share against newer diuretics and managing generics transition rather than growth initiatives.
CLINICAL PHARMACOLOGY Mechanism of Action Micropuncture studies in animals have shown that torsemide acts from within the lumen of the thick ascending portion of the loop of Henle, where it inhibits the Na/K/2CI-carrier system. Clinical pharmacology studies have confirmed this site of action in…
Worked on DEMADEX at PharmaIN? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on DEMADEX offers limited growth trajectory; career opportunities center on managing maturity, defending against generics, and optimizing market access for an established commodity product. This role suits professionals focused on managed markets, pricing strategy, or sales execution rather than innovation or product launches.